US 7,320,786 B2 | ||
Photodynamic therapy treatment for eye disease | ||
James C. Chen, Bellevue, Wash. (US) | ||
Assigned to Light Sciences Oncology, Inc., Snoqualmie, Wash. (US) | ||
Filed on Dec. 07, 2005, as Appl. No. 11/297,880. | ||
Application 11/297880 is a continuation in part of application No. 09/760362, filed on Jan. 12, 2001, abandoned. | ||
Claims priority of provisional application 60/175689, filed on Jan. 12, 2000. | ||
Prior Publication US 2006/0088530 A1, Apr. 27, 2006 | ||
Int. Cl. A61K 9/00 (2006.01); A61K 39/395 (2006.01); A01N 43/38 (2006.01) |
U.S. Cl. 424—9.6 [424/9.61; 424/143.1; 424/178.1; 514/185; 514/912] | 17 Claims |
1. A method of treating neovascular disease of the eye, comprising:
administering a conjugate to target neovascular tissue of the eye comprising:
a photosensitizing compound selected from the group consisting of chlorines, bacteriochlorophylls, phthalocyanines, porphyrins,
purpurins, merocyanines, psoralens, porfimer sodium, delta-aminolevulinic acid protoporphyrin, indocyanine green, benzoporphyrin,
methylene blue, toluidine blue, texaphyrins, pyropheophorbide compounds, and verteporfin; and
a targeting moiety that selectively binds to abnormal endothelium, wherein the targeting moiety consists of an antibody or
an antibody fragment thereof that binds to a VEGF receptor;
allowing sufficient time for the conjugate to clear from non-targeted tissue of the eye; and
illuminating the eye with a light having a wave length or waveband absorbed by the targeted photosensitizing compound to activate
the photosensitizing compound, and
wherein the light has a combination of an intensity of light of less than 500 mW/cm2 and a duration of illumination of about 4 minutes to produce a total fluence of light irradiation from between about 30 J/cm2 to about 25,000 J/cm2 which destroys the targeted neovascular tissue while the non-targeted tissue remains undamaged.
|